ABBV 65.44 Abbvie Inc. Common Stock $ABBV Hit a 52
Post# of 194
Posted On: 11/18/2014 10:04:09 AM
ABBV 65.44 Abbvie Inc. Common Stock $ABBV Hit a 52 week high of 65.58 Closing the day 09:45 at 65.44 +0.40 +0.62% With a day low of 64.78 and a total volume of 486,138.
ABBV Recent Posts: http://investorshangout.com/AbbVie-Inc-ABBV-90091/
ABBV Abbvie Inc. Common Stock Recent Headline News
Dispelling Some Of The Myths Surrounding Gilead Sciences.
Alexander J. Poulos - Seeking Alpha - 1 hr 41 mins ago
Gilead Sciences (NASDAQ: GILD ) has come under fire recently, as many are fretting about the long-term viability of the company's hepatitis C franchise (HCV). The article below will build the case for the superiority of the GILD treatment as opposed...
GILD: 101.92 (+1.48), ABBV: 65.52 (+0.48)
Merck Updates on Anti-PD-1 Drug Keytruda Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:30PM CST
Merck's (MRK) anti-PD-1 therapy, Keytruda, met the primary endpoint of progression free survival as compared to chemotherapy in a phase II study (KEYNOTE-002).
AGN: 211.95 (+2.75), MRK: 59.58 (+0.12), ABBV: 65.52 (+0.48), BMY: 58.69 (+0.26)
Will IPOs WhiteWave, Enanta Surpass Buy Points?
at Investor's Business Daily - Mon Nov 17, 5:27PM CST
With the market in a confirmed uptrend, many IPO Leaders are extended beyond their buy points. But a few, including WhiteWave Foods (WWAV) and Enanta Pharmaceuticals (ENTA), are still within striking distance. WhiteWave has been trading near a 37.25...
WWAV: 36.88 (+0.35), ABBV: 65.52 (+0.48), ENTA: 44.20 (+0.23), NVS: 95.10 (+0.72)
Jim Cramer Answers Twitter (TWTR) Questions on Gold, Gilead and More
at The Street - Mon Nov 17, 1:53PM CST
TheStreet's Jim Cramer answers Twitter (TWTR) questions on gold, Gilead (GILD), energy stocks and more.
JNJ: 108.68 (+0.38), GILD: 101.92 (+1.48), GLD: 114.68 (+0.63), ABBV: 65.52 (+0.48), TWTR: 40.80 (+0.33), NVS: 95.10 (+0.72)
Cramer: Pfizer Deal With Merck Leaves AstraZeneca In the Cold
at The Street - Mon Nov 17, 10:47AM CST
TheStreet's Jim Cramer says Pfizer's decision to buy Merck's cancer treatment business likely means an acquisition of AstraZeneca is off the table.
SHPG: 208.42 (+2.43), PFE: 30.35 (+0.03), MRK: 59.58 (+0.12), AZN: 73.07 (+0.57), ABBV: 65.52 (+0.48)
Why Top Dividend Stock Johnson & Johnson Could Plunge in 2015
George Budwell, The Motley Fool - Motley Fool - Mon Nov 17, 7:13AM CST
As the healthcare sector rolls through its third-quarter earnings, a bucolic picture is coming into focus. Earnings across the sector are soaring due to new drug launches, a frenzy of acquisitions, and vast reorganizations that have helped to stem...
JNJ: 108.68 (+0.38), GILD: 101.92 (+1.48), ABBV: 65.52 (+0.48), CELG: 105.95 (+1.59)
AbbVie to Present at Jefferies 2014 Global Healthcare Conference
PR Newswire - Mon Nov 17, 6:00AM CST
AbbVie (NYSE: ABBV) will participate in the Jefferies 2014 Global Healthcare Conference in London on Thursday, Nov. 20, 2014. Bill Chase, executive vice president and chief financial officer, will make a formal presentation on the company at 9:20 a.m. GMT (3:20 a.m. Central time.)
ABBV: 65.52 (+0.48)
7 Biggest Health Problems Americans Face
Keith Speights, The Motley Fool - Motley Fool - Sun Nov 16, 12:00PM CST
Americans include two health-related issues among the 10 most important problems facing the U.S., according to a recent Gallup survey . Healthcare in general ranked fourth on the list, with Ebola coming in at no. 8. But is Ebola really among the...
AZN: 73.07 (+0.57), LLY: 67.59 (+0.30), ABBV: 65.52 (+0.48), GSK: 46.06 (+0.18), SNY: 48.01 (+0.47), NVS: 95.10 (+0.72)
AbbVie Inc. vs. Pfizer Inc.: Which Is the Better Dividend Stock?
George Budwell, The Motley Fool - Motley Fool - Sun Nov 16, 9:20AM CST
Dividend stocks are powerful long-term investing vehicles that should be an integral part of a well balanced portfolio. Picking good dividend stocks, though, is another story altogether. High dividend yields may be an artificial by-product of a...
PFE: 30.35 (+0.03), AZN: 73.07 (+0.57), ABBV: 65.52 (+0.48)
7 Aristocrat Dividend Dogs Hit 5% To 12.75% November Upsides
Fredrik Arnold - at Seeking Alpha - Fri Nov 14, 5:10PM CST
KO: 42.90 (-0.02), HCP: 44.01 (-0.16), CLX: 100.59 (-0.43), GPC: 100.15 (+0.23), TROW: 82.34 (+0.49), NUE: 54.27 (+0.13), ED: 62.64 (+0.10), SYY: 38.93 (+0.04), LEG: 41.35 (+0.11), EMR: 63.95 (+0.21), XOM: 95.37 (+0.26), PEP: 97.95 (-0.47), T: 35.67 (-0.18), CINF: 51.00 (+0.02), ADP: 84.94 (+0.10), TGT: 66.72 (-0.41), MCD: 95.39 (-0.58), ABBV: 65.52 (+0.48), CVX: 116.33 (+0.58), AFL: 59.04 (-0.09), CL: 67.77 (-0.15)
AbbVie Presents Results from Study of ABT-414 in Patients with Glioblastoma Multiforme at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
PR Newswire - Fri Nov 14, 3:48PM CST
AbbVie (NYSE: ABBV) released updated interim results from a Phase 1 clinical trial of ABT-414 in patients with glioblastoma multiforme, an aggressive form of brain cancer, which showed that of those with measurable disease and epidermal growth factor receptor (EGFR) amplification, four of 12 patients (33%) achieved an objective response, including two whom achieved complete responses. The results from the three-arm clinical trial, which evaluated ABT-414 as a monotherapy, in combination with chemotherapy, or in combination with radiation and chemotherapy, were presented at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 13-16 in Miami.
ABBV: 65.52 (+0.48)
Where Will Google Stock Be in 10 Years?
Leo Sun, The Motley Fool - Motley Fool - Fri Nov 14, 8:00AM CST
Over the past decade, Google stock has soared over 500%, fueled by the growth in search and mobile devices. Google now controls 58% of the world's Internet searches and 85% of the mobile market via Android, and it continues to disrupt Microsoft'...
AMZN: 327.05 (+4.00), FB: 74.54 (+0.30), ABBV: 65.52 (+0.48), GOOGL: 552.05 (+5.41), GOOG: 541.10 (+4.59)
The Post AASLD Annual Meeting Hepatitis C Landscape
Leonard Yaffe - at Seeking Alpha - Fri Nov 14, 5:15AM CST
JNJ: 108.70 (+0.40), GILD: 101.98 (+1.54), MRK: 59.58 (+0.12), ABBV: 65.52 (+0.48)
If Gilead Has The Ace, Is AbbVie Holding The Big Joker?
Shock Exchange - at Seeking Alpha - Fri Nov 14, 1:55AM CST
GILD: 101.98 (+1.54), ABBV: 65.52 (+0.48)
Is Johnson & Johnson A Stock Worth Having In The Portfolio Right Now?
Abba's Aces - at Seeking Alpha - Fri Nov 14, 1:36AM CST
JNJ: 108.70 (+0.40), PFE: 30.36 (+0.04), ABBV: 65.52 (+0.48)
AbbVie's Leadership in Immunology Featured at 2014 American College of Rheumatology Annual Meeting with New Data on Investigational Medicines and HUMIRA® (adalimumab)
PR Newswire - Thu Nov 13, 8:00AM CST
AbbVie (NYSE: ABBV) announced that data from 37 abstracts related to HUMIRA® (adalimumab), rheumatologic diseases and investigational medicines will be presented at the upcoming 2014 American College of Rheumatology (ACR) Annual Meeting, November 14 - 19, in Boston. As a long-standing expert in the field of rheumatology with its experience with HUMIRA, AbbVie continues to build on its leadership with data focused on investigational medicines to create innovative solutions for rheumatologic diseases.
ABBV: 65.52 (+0.48)
Testosterone Sales Slump as Testosterone Lawsuit MDL Builds Momentum, Report Attorneys Handling National Testosterone Lawsuits
PRWeb - Thu Nov 13, 2:22AM CST
Lawyers providing legal representation for testosterone lawsuits report progress in the national multidistrict litigation for testosterone lawsuits; meanwhile, a major news source, Bloomberg Businessweek, reported on losses in the testosterone replacement therapy market. These attorneys offer timely testosterone lawsuit news updates and testosterone lawsuit case review at androgeltestosteronelawsuitcenter.com.
PFE: 30.35 (+0.03), ABBV: 65.52 (+0.48)
Achillion Pharmaceuticals: Still Bullish, But Taking Profits
Dr. Paul Nunzio DeSantis, Pharm.D - Seeking Alpha - Wed Nov 12, 4:06PM CST
By Dr. Paul Nunzio De Santis (Pharm.D.) Entry: $9.86 10/2/14 Take Profits: $14.45 11/12/14 Hold 10-20% of profits into event for M&A upside. Achillion (NASDAQ: ACHN ) has been a stellar performer since we wrote about it on October 2nd- up...
ACHN: 13.81 (+0.49), MRK: 59.58 (+0.12), ABBV: 65.52 (+0.48)
Gilead Reports Promising Data on its HCV Drug Harvoni - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:00PM CST
Gilead Sciences, Inc. (GILD) announced pooled data from certain phase II and phase III studies evaluating Harvoni.
AGN: 211.95 (+2.75), JNJ: 108.70 (+0.40), GILD: 101.98 (+1.54), ABBV: 65.52 (+0.48)
Gilead Sciences Gets Ambushed By The Patent Troll, AbbVie
Small Pharma Analyst - at Seeking Alpha - Wed Nov 12, 2:25PM CST
GILD: 101.98 (+1.54), ABBV: 65.52 (+0.48)
ABBV Recent Posts: http://investorshangout.com/AbbVie-Inc-ABBV-90091/
ABBV Abbvie Inc. Common Stock Recent Headline News
Dispelling Some Of The Myths Surrounding Gilead Sciences.
Alexander J. Poulos - Seeking Alpha - 1 hr 41 mins ago
Gilead Sciences (NASDAQ: GILD ) has come under fire recently, as many are fretting about the long-term viability of the company's hepatitis C franchise (HCV). The article below will build the case for the superiority of the GILD treatment as opposed...
GILD: 101.92 (+1.48), ABBV: 65.52 (+0.48)
Merck Updates on Anti-PD-1 Drug Keytruda Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:30PM CST
Merck's (MRK) anti-PD-1 therapy, Keytruda, met the primary endpoint of progression free survival as compared to chemotherapy in a phase II study (KEYNOTE-002).
AGN: 211.95 (+2.75), MRK: 59.58 (+0.12), ABBV: 65.52 (+0.48), BMY: 58.69 (+0.26)
Will IPOs WhiteWave, Enanta Surpass Buy Points?
at Investor's Business Daily - Mon Nov 17, 5:27PM CST
With the market in a confirmed uptrend, many IPO Leaders are extended beyond their buy points. But a few, including WhiteWave Foods (WWAV) and Enanta Pharmaceuticals (ENTA), are still within striking distance. WhiteWave has been trading near a 37.25...
WWAV: 36.88 (+0.35), ABBV: 65.52 (+0.48), ENTA: 44.20 (+0.23), NVS: 95.10 (+0.72)
Jim Cramer Answers Twitter (TWTR) Questions on Gold, Gilead and More
at The Street - Mon Nov 17, 1:53PM CST
TheStreet's Jim Cramer answers Twitter (TWTR) questions on gold, Gilead (GILD), energy stocks and more.
JNJ: 108.68 (+0.38), GILD: 101.92 (+1.48), GLD: 114.68 (+0.63), ABBV: 65.52 (+0.48), TWTR: 40.80 (+0.33), NVS: 95.10 (+0.72)
Cramer: Pfizer Deal With Merck Leaves AstraZeneca In the Cold
at The Street - Mon Nov 17, 10:47AM CST
TheStreet's Jim Cramer says Pfizer's decision to buy Merck's cancer treatment business likely means an acquisition of AstraZeneca is off the table.
SHPG: 208.42 (+2.43), PFE: 30.35 (+0.03), MRK: 59.58 (+0.12), AZN: 73.07 (+0.57), ABBV: 65.52 (+0.48)
Why Top Dividend Stock Johnson & Johnson Could Plunge in 2015
George Budwell, The Motley Fool - Motley Fool - Mon Nov 17, 7:13AM CST
As the healthcare sector rolls through its third-quarter earnings, a bucolic picture is coming into focus. Earnings across the sector are soaring due to new drug launches, a frenzy of acquisitions, and vast reorganizations that have helped to stem...
JNJ: 108.68 (+0.38), GILD: 101.92 (+1.48), ABBV: 65.52 (+0.48), CELG: 105.95 (+1.59)
AbbVie to Present at Jefferies 2014 Global Healthcare Conference
PR Newswire - Mon Nov 17, 6:00AM CST
AbbVie (NYSE: ABBV) will participate in the Jefferies 2014 Global Healthcare Conference in London on Thursday, Nov. 20, 2014. Bill Chase, executive vice president and chief financial officer, will make a formal presentation on the company at 9:20 a.m. GMT (3:20 a.m. Central time.)
ABBV: 65.52 (+0.48)
7 Biggest Health Problems Americans Face
Keith Speights, The Motley Fool - Motley Fool - Sun Nov 16, 12:00PM CST
Americans include two health-related issues among the 10 most important problems facing the U.S., according to a recent Gallup survey . Healthcare in general ranked fourth on the list, with Ebola coming in at no. 8. But is Ebola really among the...
AZN: 73.07 (+0.57), LLY: 67.59 (+0.30), ABBV: 65.52 (+0.48), GSK: 46.06 (+0.18), SNY: 48.01 (+0.47), NVS: 95.10 (+0.72)
AbbVie Inc. vs. Pfizer Inc.: Which Is the Better Dividend Stock?
George Budwell, The Motley Fool - Motley Fool - Sun Nov 16, 9:20AM CST
Dividend stocks are powerful long-term investing vehicles that should be an integral part of a well balanced portfolio. Picking good dividend stocks, though, is another story altogether. High dividend yields may be an artificial by-product of a...
PFE: 30.35 (+0.03), AZN: 73.07 (+0.57), ABBV: 65.52 (+0.48)
7 Aristocrat Dividend Dogs Hit 5% To 12.75% November Upsides
Fredrik Arnold - at Seeking Alpha - Fri Nov 14, 5:10PM CST
KO: 42.90 (-0.02), HCP: 44.01 (-0.16), CLX: 100.59 (-0.43), GPC: 100.15 (+0.23), TROW: 82.34 (+0.49), NUE: 54.27 (+0.13), ED: 62.64 (+0.10), SYY: 38.93 (+0.04), LEG: 41.35 (+0.11), EMR: 63.95 (+0.21), XOM: 95.37 (+0.26), PEP: 97.95 (-0.47), T: 35.67 (-0.18), CINF: 51.00 (+0.02), ADP: 84.94 (+0.10), TGT: 66.72 (-0.41), MCD: 95.39 (-0.58), ABBV: 65.52 (+0.48), CVX: 116.33 (+0.58), AFL: 59.04 (-0.09), CL: 67.77 (-0.15)
AbbVie Presents Results from Study of ABT-414 in Patients with Glioblastoma Multiforme at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
PR Newswire - Fri Nov 14, 3:48PM CST
AbbVie (NYSE: ABBV) released updated interim results from a Phase 1 clinical trial of ABT-414 in patients with glioblastoma multiforme, an aggressive form of brain cancer, which showed that of those with measurable disease and epidermal growth factor receptor (EGFR) amplification, four of 12 patients (33%) achieved an objective response, including two whom achieved complete responses. The results from the three-arm clinical trial, which evaluated ABT-414 as a monotherapy, in combination with chemotherapy, or in combination with radiation and chemotherapy, were presented at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 13-16 in Miami.
ABBV: 65.52 (+0.48)
Where Will Google Stock Be in 10 Years?
Leo Sun, The Motley Fool - Motley Fool - Fri Nov 14, 8:00AM CST
Over the past decade, Google stock has soared over 500%, fueled by the growth in search and mobile devices. Google now controls 58% of the world's Internet searches and 85% of the mobile market via Android, and it continues to disrupt Microsoft'...
AMZN: 327.05 (+4.00), FB: 74.54 (+0.30), ABBV: 65.52 (+0.48), GOOGL: 552.05 (+5.41), GOOG: 541.10 (+4.59)
The Post AASLD Annual Meeting Hepatitis C Landscape
Leonard Yaffe - at Seeking Alpha - Fri Nov 14, 5:15AM CST
JNJ: 108.70 (+0.40), GILD: 101.98 (+1.54), MRK: 59.58 (+0.12), ABBV: 65.52 (+0.48)
If Gilead Has The Ace, Is AbbVie Holding The Big Joker?
Shock Exchange - at Seeking Alpha - Fri Nov 14, 1:55AM CST
GILD: 101.98 (+1.54), ABBV: 65.52 (+0.48)
Is Johnson & Johnson A Stock Worth Having In The Portfolio Right Now?
Abba's Aces - at Seeking Alpha - Fri Nov 14, 1:36AM CST
JNJ: 108.70 (+0.40), PFE: 30.36 (+0.04), ABBV: 65.52 (+0.48)
AbbVie's Leadership in Immunology Featured at 2014 American College of Rheumatology Annual Meeting with New Data on Investigational Medicines and HUMIRA® (adalimumab)
PR Newswire - Thu Nov 13, 8:00AM CST
AbbVie (NYSE: ABBV) announced that data from 37 abstracts related to HUMIRA® (adalimumab), rheumatologic diseases and investigational medicines will be presented at the upcoming 2014 American College of Rheumatology (ACR) Annual Meeting, November 14 - 19, in Boston. As a long-standing expert in the field of rheumatology with its experience with HUMIRA, AbbVie continues to build on its leadership with data focused on investigational medicines to create innovative solutions for rheumatologic diseases.
ABBV: 65.52 (+0.48)
Testosterone Sales Slump as Testosterone Lawsuit MDL Builds Momentum, Report Attorneys Handling National Testosterone Lawsuits
PRWeb - Thu Nov 13, 2:22AM CST
Lawyers providing legal representation for testosterone lawsuits report progress in the national multidistrict litigation for testosterone lawsuits; meanwhile, a major news source, Bloomberg Businessweek, reported on losses in the testosterone replacement therapy market. These attorneys offer timely testosterone lawsuit news updates and testosterone lawsuit case review at androgeltestosteronelawsuitcenter.com.
PFE: 30.35 (+0.03), ABBV: 65.52 (+0.48)
Achillion Pharmaceuticals: Still Bullish, But Taking Profits
Dr. Paul Nunzio DeSantis, Pharm.D - Seeking Alpha - Wed Nov 12, 4:06PM CST
By Dr. Paul Nunzio De Santis (Pharm.D.) Entry: $9.86 10/2/14 Take Profits: $14.45 11/12/14 Hold 10-20% of profits into event for M&A upside. Achillion (NASDAQ: ACHN ) has been a stellar performer since we wrote about it on October 2nd- up...
ACHN: 13.81 (+0.49), MRK: 59.58 (+0.12), ABBV: 65.52 (+0.48)
Gilead Reports Promising Data on its HCV Drug Harvoni - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:00PM CST
Gilead Sciences, Inc. (GILD) announced pooled data from certain phase II and phase III studies evaluating Harvoni.
AGN: 211.95 (+2.75), JNJ: 108.70 (+0.40), GILD: 101.98 (+1.54), ABBV: 65.52 (+0.48)
Gilead Sciences Gets Ambushed By The Patent Troll, AbbVie
Small Pharma Analyst - at Seeking Alpha - Wed Nov 12, 2:25PM CST
GILD: 101.98 (+1.54), ABBV: 65.52 (+0.48)
(0)
(0)AbbVie Inc. (ABBV) Stock Research Links
Scroll down for more posts ▼